Secondaries announced 9.7.2016
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sage Therapeutics, Inc. Symbol: SAGE Price: Last trade $41.34 Trade Date: 9/9 Shares: 3.63 million Underwriter(s) J.P. Morgan, Goldman Sachs Co[…]
